As we observe Rare Disease Day today, let us take a look at seven drugs poised to be approved to address rare diseases in ...

Orladeyo, BioCryst's main revenue source, saw impressive growth in 2024, but faces significant competition. Click here to ...

BioCryst Pharmaceuticals, a rare disease biotech, shows strong revenue growth from ORLADEYO and a healthy cash position. See ...

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced the initiation of the ...

ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)——FY 2025 ORLADEYO ...

The current approval of Takeda’s Takhzyro pre-filled pen is an addition to the existing 150 mg and 300 mg pre-filled syringes ...

Q4 2024 Earnings Call Transcript February 24, 2025 BioCryst Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.13 EPS, expectations were $-0.07. Operator: Good morning, and ...

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., ...

Zurich: Takeda has announced that the European Medicines Agency (EMA) has given approval for an additional 2 mL pre-filled ...

Department of Preventive Dentistry, Peking University School and Hospital of Stomatology & National Center for Stomatology & National Clinical Research Center for Oral Diseases & National Engineering ...